| Field | Row 1 |
|---|---|
| adsh | 0001558370-25-007494 |
| cik | 791908 |
| name | XOMA ROYALTY CORP |
| sic | 2834 |
| countryba | US |
| stprba | CA |
| cityba | EMERYVILLE |
| zipba | 94608 |
| bas1 | 2200 POWELL STREET |
| bas2 | SUITE 310 |
| baph | 510-204-7239 |
| countryma | US |
| stprma | CA |
| cityma | EMERYVILLE |
| zipma | 94608 |
| mas1 | 2200 POWELL STREET |
| mas2 | SUITE 310 |
| countryinc | |
| stprinc | |
| ein | 522154066 |
| former | XOMA CORP |
| changed | 20120119 |
| afs | 4-NON |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250513 |
| accepted | 2025-05-13 07:46:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | xoma-20250331x10q_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001558370-25-007494 | 20241231 | Accounts And Other Receivables Net Current | 1300000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Viracta Therapeutics Inc.; Type Of Arrangement= Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20250331 | Accrued Preferred Stock Dividend Current | 1368000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Amortization Of Financing Costs And Discounts | 427000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Amortization Of Intangible Assets | 544000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 142401000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Common Stock Shares Authorized | 277333332.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Comprehensive Income Net Of Tax | -8595000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240630 | Contingent Consideration Under Purchase Agreements | 0.0000 | USD | 0 | 0001558370-25-007494 | Contingent Consideration By Type= Contingent Consideration Regulatory Milestones; Counterparty Name= Ladrx; Product Or Service= Aldoxorubicin; Type Of Arrangement= Assignment And Assumption Agreement And Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20240331 | Depreciation Nonproduction | 2000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Single Reportable Segment; | ||
| 0001558370-25-007494 | 20241231 | Equity Securities Fv Ni | 3500000.0000 | USD | 0 | us-gaap/2024 | Schedule Of Equity Method Investment Equity Method Investee Name= Rezolute Inc; | ||
| 0001558370-25-007494 | 20240331 | Equity Securities Fv Ni Realized Gain Loss | 252000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Equity Securities Fv Ni Realized Gain Loss | -1100000.0000 | USD | 1 | us-gaap/2024 | Schedule Of Equity Method Investment Equity Method Investee Name= Rezolute Inc; | ||
| 0001558370-25-007494 | 20240331 | Income Not From Contract With Customer Cost Recovery Method | 0.0000 | USD | 1 | 0001558370-25-007494 | Counterparty Name= Viracta Therapeutics Inc.; Type Of Arrangement= Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20250331 | Income Not From Contract With Customer Cost Recovery Method | 5525000.0000 | USD | 1 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Income Not From Contract With Customer Cost Recovery Method | 5500000.0000 | USD | 1 | 0001558370-25-007494 | Counterparty Name= Viracta Therapeutics Inc.; Type Of Arrangement= Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20240331 | Income Not From Contract With Customer Effective Interest Rate Method | 0.0000 | USD | 1 | 0001558370-25-007494 | Counterparty Name= Aptevo; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20240331 | Increase Decrease In Accounts Payable And Accrued Liabilities | -105000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Intangible Assets Net Excluding Goodwill | 25365000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Investment Warrants Noncurrent | 605000.0000 | USD | 0 | 0001558370-25-007494 | Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001558370-25-007494 | 20250331 | Liabilities And Stockholders Equity | 212750000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Liabilities Current | 24374000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Liabilities Current | 20434000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Milestone Assets Noncurrent | 3307000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Net Cash Provided By Used In Investing Activities | -6693000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Other Assets Noncurrent | 1861000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Other Nonoperating Income Expense | -95000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20210731 | Payment Of Consideration Under Agreements Investing Activities | 7000000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Kuros Biosciences Ag Kuros Us Llc And Kuros Royalty Fund Us Llc; Type Of Arrangement= Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20230630 | Payment Of Consideration Under Agreements Investing Activities | 50000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Aptevo; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20250331 | Payment Of Consideration Under Agreements Investing Activities | 8000000.0000 | USD | 1 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Payment Of Consideration Under Agreements Investing Activities | 6000000.0000 | USD | 1 | 0001558370-25-007494 | Counterparty Name= Affitech Research As; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20240331 | Payments Of Dividends | 1368000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Preferred Stock Dividend Rate Percentage | 0.0838 | pure | 4 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; | ||
| 0001558370-25-007494 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0500 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Preferred Stock Shares Issued | 5003.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Convertible Preferred Stock; | ||
| 0001558370-25-007494 | 20241231 | Preferred Stock Shares Outstanding | 5003.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Convertible Preferred Stock; | ||
| 0001558370-25-007494 | 20250331 | Preferred Stock Value | USD | 0 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; | |||
| 0001558370-25-007494 | 20241231 | Prepaid Expense And Other Assets Current | 2076000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Receipts Under Agreements Investing Activities | 400000.0000 | USD | 1 | 0001558370-25-007494 | Counterparty Name= Ladrx; Type Of Arrangement= Assignment And Assumption Agreement And Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20240430 | Revenue From Contract With Customer Excluding Assessed Tax | 5000000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Rezolute Inc; Type Of Arrangement= License Agreement; | ||
| 0001558370-25-007494 | 20240331 | Revenue Not From Contract With Customer Units Of Revenue Method | 500000.0000 | USD | 1 | 0001558370-25-007494 | Counterparty Name= Health Care Royalty Partners Two Limited Partners; Type Of Arrangement= Royalty Interest Acquisition Agreements; | ||
| 0001558370-25-007494 | 20250331 | Revenues | 15912000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20211031 | Royalty And Commercial Payment Receivables Cost Recovery Method Long Term | 14000000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Affitech Research As; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20231231 | Shares Outstanding | 5000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Convertible Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20240331 | Shares Outstanding | 984000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20241231 | Shares Outstanding | 5000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Convertible Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20241231 | Shares Outstanding | 984000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20240331 | Stockholders Equity | -1231831000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001558370-25-007494 | 20250331 | Stockholders Equity | 118000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-007494 | 20250331 | Stockholders Equity | 90000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-007494 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 21000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-007494 | 20250331 | Stock Repurchased And Retired During Period Shares | 26488.0000 | shares | 5 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 11580000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Accrued And Other Liabilities Current | 5752000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Amortization Of Financing Costs And Discounts | 427000.0000 | USD | 1 | us-gaap/2024 | Debt Instrument= Blue Owl Commercial Payment Backed Loan Agreement Initial Term Loan; | ||
| 0001558370-25-007494 | 20241231 | Asset Acquisition Contingent Consideration Liability Noncurrent | 3214000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001558370-25-007494 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -17149000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Common Stock Shares Outstanding | 11952889.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Deferred Income Noncurrent | 4410000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | General And Administrative Expense | 8461000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Income Not From Contract With Customer Effective Interest Rate Method | 5817000.0000 | USD | 1 | 0001558370-25-007494 | Counterparty Name= Affitech Research As; Product Or Service= Vabysmo; | ||
| 0001558370-25-007494 | 20250331 | Income Not From Contract With Customer Effective Interest Rate Method Cash Flow Impact | 1743000.0000 | USD | 1 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Income Taxes Paid Net | 277000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Increase Decrease In Operating Lease Liability | -15000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Intangible Assets Net Excluding Goodwill | 25909000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Interest Expense Debt | 3467000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Single Reportable Segment; | ||
| 0001558370-25-007494 | 20241231 | Liabilities | 139356000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Liabilities | 128121000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Liabilities And Stockholders Equity | 221277000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Milestone Assets Noncurrent | 3214000.0000 | USD | 0 | 0001558370-25-007494 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001558370-25-007494 | 20240331 | Net Cash Provided By Used In Financing Activities | -4956000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Operating Expenses | 9983000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240430 | Operating Lease Right Of Use Asset | 0.0000 | USD | 0 | us-gaap/2024 | Property Plant And Equipment By Type= Leased Facilities San Francisco California; | ||
| 0001558370-25-007494 | 20250331 | Operating Lease Right Of Use Asset | 304000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20211031 | Payment Of Consideration Under Agreements Investing Activities | 6000000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Affitech Research As; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20241031 | Payment Of Consideration Under Agreements Investing Activities | 15000000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Twist Bioscience Corporation; Type Of Arrangement= Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20241231 | Payment Of Consideration Under Agreements Investing Activities | 1000000.0000 | USD | 4 | 0001558370-25-007494 | Contingent Consideration By Type= Contingent Consideration Regulatory Milestones; Counterparty Name= Ladrx; Type Of Arrangement= Assignment And Assumption Agreement And Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20250331 | Payments For Repurchase Of Common Stock | 545000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Preferred Stock Shares Authorized | 1000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Preferred Stock Shares Issued | 5003.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Convertible Preferred Stock; | ||
| 0001558370-25-007494 | 20241231 | Preferred Stock Value | USD | 0 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; | |||
| 0001558370-25-007494 | 20250331 | Receipts Under Agreements Investing Activities | 11100000.0000 | USD | 1 | 0001558370-25-007494 | Counterparty Name= Affitech Research As; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Janssen Biotech Inc.; Type Of Arrangement= License Agreement; | ||
| 0001558370-25-007494 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Takeda Pharmaceutical Company Limited; Type Of Arrangement= Collaboration Agreement; | ||
| 0001558370-25-007494 | 20241231 | Revenue From Contract With Customer Excluding Assessed Tax | 500000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Alexion; Type Of Arrangement= License Agreement; | ||
| 0001558370-25-007494 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 4000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Revenues | 1490000.0000 | USD | 1 | us-gaap/2024 | Geographical= C H; | ||
| 0001558370-25-007494 | 20250331 | Revenues | 6095000.0000 | USD | 1 | us-gaap/2024 | Geographical= C H; | ||
| 0001558370-25-007494 | 20240430 | Royalty And Commercial Payment Receivables Cost Recovery Method Long Term | 22000000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Dare; Type Of Arrangement= Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20250228 | Royalty And Commercial Payment Receivables Cost Recovery Method Long Term | 4400000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Castle Creek Biosciences Inc; Type Of Arrangement= Royalty Financing Agreement; | ||
| 0001558370-25-007494 | 20250331 | Royalty And Commercial Payment Receivables Cost Recovery Method Short Term | 413000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Royalty And Commercial Payment Receivables Cost Recovery Method Short Term | 0.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Dare; Type Of Arrangement= Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20250331 | Royalty And Commercial Payment Receivables Effective Interest Rate Method Short Term | 12240000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20231231 | Shares Outstanding | 11495000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-007494 | 20240331 | Shares Outstanding | 5000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Convertible Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20240331 | Shares Outstanding | 2000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20250331 | Shares Outstanding | 5000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Convertible Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20231231 | Stockholders Equity | 1311809000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007494 | 20250331 | Stock Repurchased And Retired During Period Shares | 25828.0000 | shares | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 17781000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Accounts Payable Current | 1053000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Accrued Preferred Stock Dividend Current | 1368000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | 118000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Additional Paid In Capital | 1318766000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Additional Paid In Capital | 1319607000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Amortization Of Financing Costs And Discounts | 306000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Asset Acquisition Contingent Consideration Liability Noncurrent | 3300000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Kinnate Cvr Holders; Type Of Arrangement= Contingent Value Rights Agreement; | ||
| 0001558370-25-007494 | 20250331 | Asset Acquisition Contingent Consideration Liability Noncurrent | 3307000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001558370-25-007494 | 20250331 | Assets | 212750000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Assets Current | 125604000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Assets Current | 113225000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Cash And Cash Equivalents At Carrying Value | 101654000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 159550000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001558370-25-007494 | 20211031 | Contingent Consideration Under Purchase Agreements | 8000000.0000 | USD | 0 | 0001558370-25-007494 | Contingent Consideration By Type= Contingent Consideration Regulatory Milestones; Counterparty Name= Affitech Research As; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20241231 | Deferred Income Noncurrent | 4400000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Health Care Royalty Partners Two Limited Partners; Type Of Arrangement= Royalty Interest Acquisition Agreements; | ||
| 0001558370-25-007494 | 20250331 | Deferred Income Noncurrent | 4100000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Health Care Royalty Partners Two Limited Partners; Type Of Arrangement= Royalty Interest Acquisition Agreements; | ||
| 0001558370-25-007494 | 20250331 | Earnings Per Share Basic | 0.0600 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | General And Administrative Expense | 8146000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Income Not From Contract With Customer Cost Recovery Method | 5525000.0000 | USD | 1 | 0001558370-25-007494 | Counterparty Name= Viracta Therapeutics Inc.; Product Or Service= Tovorafenib; | ||
| 0001558370-25-007494 | 20240331 | Interest Paid Net | 3780000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Long Term Debt Current | 11394000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Long Term Debt Noncurrent | 99934000.0000 | USD | 0 | us-gaap/2024 | Debt Instrument= Blue Owl Commercial Payment Backed Loan Agreement Initial Term Loan; | ||
| 0001558370-25-007494 | 20241231 | Milestone Assets Noncurrent | 3214000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20240331 | Net Cash Provided By Used In Operating Activities | -4947000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Net Income Loss Available To Common Stockholders Diluted | 999000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent | 45000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Payment Of Consideration Under Agreements Investing Activities | 1000000.0000 | USD | 4 | 0001558370-25-007494 | Contingent Consideration By Type= Contingent Consideration Sales Milestones; Counterparty Name= Ladrx; Type Of Arrangement= Assignment And Assumption Agreement And Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20250331 | Payment Of Consideration Under Agreements Investing Activities | 3000000.0000 | USD | 1 | 0001558370-25-007494 | Contingent Consideration By Type= Contingent Consideration Sales Milestones Four; | ||
| 0001558370-25-007494 | 20250331 | Payments Related To Tax Withholding For Share Based Compensation | 240000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Preferred Stock Shares Issued | 1600.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; | ||
| 0001558370-25-007494 | 20240331 | Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 1956000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20230630 | Receipts Under Agreements Investing Activities | 500000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Aptevo; Range= Minimum; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20240331 | Repayments Of Long Term Debt | 3616000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Restricted Cash Current | 1330000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Retained Earnings Accumulated Deficit | -1237057000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Retained Earnings Accumulated Deficit | -1235235000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Rezolute Inc; Type Of Arrangement= License Agreement; | ||
| 0001558370-25-007494 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Asset Acquisition= Pulmokine; | ||
| 0001558370-25-007494 | 20240331 | Revenues | 1490000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Single Reportable Segment; | ||
| 0001558370-25-007494 | 20210331 | Royalty And Commercial Payment Receivables Cost Recovery Method Long Term | 13500000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Viracta Therapeutics Inc.; Type Of Arrangement= Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20230630 | Royalty And Commercial Payment Receivables Cost Recovery Method Long Term | 6000000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Ladrx; Type Of Arrangement= Assignment And Assumption Agreement And Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20241231 | Royalty And Commercial Payment Receivables Cost Recovery Method Long Term | 55936000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Royalty And Commercial Payment Receivables Cost Recovery Method Short Term | 0.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Twist Bioscience Corporation; Type Of Arrangement= Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20250331 | Royalty And Commercial Payment Receivables Effective Interest Rate Method Long Term | 4857000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20241231 | Royalty And Commercial Payment Receivables Effective Interest Rate Method Short Term | 14763000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Shares Outstanding | 984000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20250331 | Shares Outstanding | 11953000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-007494 | 20231231 | Stockholders Equity | 86000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-007494 | 20240331 | Stockholders Equity | 49000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20241231 | Stockholders Equity | 49000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20240331 | Stock Issued During Period Shares Stock Options Exercised | 135000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-007494 | 20240331 | Stock Issued During Period Value Employee Benefit Plan | 118000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Stock Issued During Period Value Employee Benefit Plan | 118000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007494 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 622000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 85000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 11969000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Accounts Payable Current | 2319000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings | 1368000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings | 1368000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007494 | 20240331 | Amortization Of Financing Costs And Discounts | 306000.0000 | USD | 1 | us-gaap/2024 | Debt Instrument= Blue Owl Commercial Payment Backed Loan Agreement Initial Term Loan; | ||
| 0001558370-25-007494 | 20250331 | Cash And Cash Equivalents At Carrying Value | 90265000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Common Stock Shares Issued | 11952889.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Common Stock Value | 90000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20230331 | Contingent Consideration Under Purchase Agreements | 50000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Aptevo; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20240331 | Contingent Consideration Under Purchase Agreements | 3000000.0000 | USD | 0 | 0001558370-25-007494 | Contingent Consideration By Type= Contingent Consideration Sales Milestones Three; Counterparty Name= Affitech Research As; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20250331 | Depreciation Nonproduction | 3000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Single Reportable Segment; | ||
| 0001558370-25-007494 | 20250331 | Dividends Payable Current And Noncurrent | 1368000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Equity Securities Fv Ni | 3529000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Interest Expense Debt | 3551000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Single Reportable Segment; | ||
| 0001558370-25-007494 | 20241231 | Long Term Debt Noncurrent | 106875000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Long Term Debt Noncurrent | 99934000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Milestone Assets Noncurrent | 3307000.0000 | USD | 0 | 0001558370-25-007494 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001558370-25-007494 | 20241231 | Operating Lease Liability Current | 446000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Operating Lease Payments Non Cash | -17000.0000 | USD | 1 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20231031 | Operating Lease Right Of Use Asset | 400000.0000 | USD | 0 | us-gaap/2024 | Property Plant And Equipment By Type= Leased Facilities Two Emeryville California; | ||
| 0001558370-25-007494 | 20240331 | Other Nonoperating Income Expense | 1960000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Payment Of Consideration Under Agreements Investing Activities | 15000000.0000 | USD | 1 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20240331 | Payments For Repurchase Of Common Stock | 13000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Preferred Stock Shares Outstanding | 1600.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; | ||
| 0001558370-25-007494 | 20250331 | Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 325000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Profit Loss | -8595000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Receipts Under Agreements Investing Activities | 600000.0000 | USD | 1 | 0001558370-25-007494 | Counterparty Name= Aptevo; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20240331 | Research And Development Expense | 33000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Revenue Not From Contract With Customer Units Of Revenue Method | 317000.0000 | USD | 1 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20240331 | Revenues | 1490000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Accounts And Other Receivables Net Current | 5544000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Accrued And Other Liabilities Current | 1221000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20241231 | Asset Acquisition Contingent Consideration Liability Noncurrent | 3214000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Common Stock Shares Authorized | 277333332.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Comprehensive Income Net Of Tax | 2412000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Deferred Income Current | 1361000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Defined Contribution Plan Issuance Of Common Stock For Services Or Claims | 118000.0000 | USD | 1 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Defined Contribution Plan Issuance Of Common Stock For Services Or Claims | 141000.0000 | USD | 1 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Equity Securities Fv Ni | 2382000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Equity Securities Fv Ni Realized Gain Loss | 300000.0000 | USD | 1 | us-gaap/2024 | Schedule Of Equity Method Investment Equity Method Investee Name= Rezolute Inc; | ||
| 0001558370-25-007494 | 20250331 | Income Not From Contract With Customer Effective Interest Rate Method | 6070000.0000 | USD | 1 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Income Not From Contract With Customer Effective Interest Rate Method | 5800000.0000 | USD | 1 | 0001558370-25-007494 | Counterparty Name= Affitech Research As; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20250331 | Increase Decrease In Operating Lease Liability | -108000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Interest Expense Debt | 3467000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Long Term Debt Current | 13697000.0000 | USD | 0 | us-gaap/2024 | Debt Instrument= Blue Owl Commercial Payment Backed Loan Agreement Initial Term Loan; | ||
| 0001558370-25-007494 | 20250331 | Milestone Assets Noncurrent | 3300000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Kinnate Cvr Holders; Type Of Arrangement= Contingent Value Rights Agreement; | ||
| 0001558370-25-007494 | 20250331 | Milestone Assets Noncurrent | 3307000.0000 | USD | 0 | 0001558370-25-007494 | Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001558370-25-007494 | 20250331 | Net Income Loss | 2367000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Net Income Loss Available To Common Stockholders Basic | 705000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Operating Lease Liability Noncurrent | 362000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20230630 | Payment Of Consideration Under Agreements Investing Activities | 5000000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Ladrx; Type Of Arrangement= Assignment And Assumption Agreement And Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20250331 | Payments Of Dividends | 1368000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Preferred Stock Dividend Rate Percentage | 0.0838 | pure | 1 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; | ||
| 0001558370-25-007494 | 20241231 | Preferred Stock Par Or Stated Value Per Share | 0.0500 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Preferred Stock Shares Outstanding | 984000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; | ||
| 0001558370-25-007494 | 20241231 | Preferred Stock Value | 49000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; | ||
| 0001558370-25-007494 | 20250331 | Preferred Stock Value | USD | 0 | us-gaap/2024 | Class Of Stock= Convertible Preferred Stock; | |||
| 0001558370-25-007494 | 20250331 | Profit Loss | 2367000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Research And Development Expense | 1293000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Single Reportable Segment; | ||
| 0001558370-25-007494 | 20241231 | Restricted Cash Noncurrent | 3432000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 1000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 3000000.0000 | USD | 74 | us-gaap/2024 | Counterparty Name= Takeda Pharmaceutical Company Limited; Type Of Arrangement= Collaboration Agreement; | ||
| 0001558370-25-007494 | 20240331 | Revenue Not From Contract With Customer Units Of Revenue Method | 490000.0000 | USD | 1 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Revenues | 5817000.0000 | USD | 1 | us-gaap/2024 | Geographical= U S; | ||
| 0001558370-25-007494 | 20190930 | Royalty And Commercial Payment Receivables Cost Recovery Method Long Term | 10000000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Palobiofarma S L; Type Of Arrangement= Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20241231 | Shares Outstanding | 2000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20231231 | Stockholders Equity | 49000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20250331 | Stock Issued During Period Shares Employee Benefit Plan | 5000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-007494 | 20250331 | Stock Issued During Period Value Employee Benefit Plan | 141000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 1000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-007494 | 20240331 | Stock Repurchased And Retired During Period Shares | 1000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-007494 | 20241231 | Royalty And Commercial Payment Receivables Effective Interest Rate Method Long Term | 4970000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Stock Issued During Period Value Employee Benefit Plan | 141000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007494 | 20250331 | Stock Repurchased And Retired During Period Shares | 25000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-007494 | 20250331 | Stock Repurchased And Retired During Period Value | 545000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001558370-25-007494 | 20241231 | Accounts And Other Receivables Net Current | 1839000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Accounts And Other Receivables Net Current | 1500000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Viracta Therapeutics Inc.; Type Of Arrangement= Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | 73000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 2856000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 2856000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007494 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0075 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Common Stock Shares Issued | 11952377.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Common Stock Value | 90000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Deferred Income Current | 1400000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Health Care Royalty Partners Two Limited Partners; Type Of Arrangement= Royalty Interest Acquisition Agreements; | ||
| 0001558370-25-007494 | 20240331 | Earnings Per Share Basic | -0.8600 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Equity Securities Fv Ni | 2400000.0000 | USD | 0 | us-gaap/2024 | Schedule Of Equity Method Investment Equity Method Investee Name= Rezolute Inc; | ||
| 0001558370-25-007494 | 20250331 | Income Not From Contract With Customer Effective Interest Rate Method | 300000.0000 | USD | 1 | 0001558370-25-007494 | Counterparty Name= Aptevo; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20250331 | Increase Decrease In Accounts And Other Receivables | 3705000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20161231 | Increase Decrease In Deferred Revenue | 18000000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Health Care Royalty Partners Two Limited Partners; Type Of Arrangement= Royalty Interest Acquisition Agreements; | ||
| 0001558370-25-007494 | 20240331 | Increase Decrease In Deferred Revenue | -490000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -213000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Long Term Debt Current | 13697000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Preferred Stock Shares Issued | 984000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; | ||
| 0001558370-25-007494 | 20250331 | Net Cash Provided By Used In Financing Activities | -6894000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Net Income Loss | -8595000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001558370-25-007494 | 20250331 | Net Income Loss | 2367000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Single Reportable Segment; | ||
| 0001558370-25-007494 | 20250331 | Operating Income Loss | 5929000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Operating Lease Liability Noncurrent | 483000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Other Nonoperating Income Expense | -95000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Single Reportable Segment; | ||
| 0001558370-25-007494 | 20240430 | Payment Of Consideration Under Agreements Investing Activities | 22000000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Dare; Type Of Arrangement= Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20240331 | Payments To Acquire Property Plant And Equipment | 17000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Preferred Stock Dividend Rate Percentage | 0.0862 | pure | 1 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; | ||
| 0001558370-25-007494 | 20241231 | Preferred Stock Shares Outstanding | 1600.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; | ||
| 0001558370-25-007494 | 20241231 | Property Plant And Equipment Net | 32000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Repayments Of Long Term Debt | 5066000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Janssen Biotech Inc.; Type Of Arrangement= License Agreement; | ||
| 0001558370-25-007494 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 4000000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Takeda Pharmaceutical Company Limited; Type Of Arrangement= Collaboration Agreement; | ||
| 0001558370-25-007494 | 20250331 | Revenues | 15912000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Single Reportable Segment; | ||
| 0001558370-25-007494 | 20250331 | Revenues | 4000000.0000 | USD | 1 | us-gaap/2024 | Geographical= Asia Pacific; | ||
| 0001558370-25-007494 | 20241031 | Royalty And Commercial Payment Receivables Cost Recovery Method Long Term | 15000000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Twist Bioscience Corporation; Type Of Arrangement= Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20250331 | Share Based Compensation | 1983000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20231231 | Shares Outstanding | 984000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20231231 | Shares Outstanding | 2000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20240331 | Shares Outstanding | 11636000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-007494 | 20250331 | Shares Outstanding | 2000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20240331 | Stockholders Equity | 82341000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Stockholders Equity | 87000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-007494 | 20241231 | Stockholders Equity | 81921000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Stockholders Equity | 73000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-007494 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 21000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 621000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007494 | 20240331 | Stock Repurchased And Retired During Period Value | 13000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001558370-25-007494 | 20250331 | Stock Repurchased And Retired During Period Value | 600000.0000 | USD | 5 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Accrual Of Contingent Consideration Under Purchase Agreements | 3000000.0000 | USD | 1 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings | 1368000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings | 1368000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007494 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1983000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1983000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007494 | 20250331 | Amortization Of Intangible Assets | 500000.0000 | USD | 1 | us-gaap/2024 | Asset Acquisition= Pulmokine; | ||
| 0001558370-25-007494 | 20250331 | Amortization Of Intangible Assets | 544000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Single Reportable Segment; | ||
| 0001558370-25-007494 | 20250331 | Asset Acquisition Contingent Consideration Liability Noncurrent | 3307000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Asset Acquisition Contingent Consideration Liability Noncurrent | 3307000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001558370-25-007494 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 106416000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Change In Fair Value Of Available For Sale Debt Securities Cash Equivalents | 45000.0000 | USD | 1 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20241231 | Common Stock Shares Outstanding | 11952377.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20230630 | Contingent Consideration Under Purchase Agreements | 1000000.0000 | USD | 0 | 0001558370-25-007494 | Contingent Consideration By Type= Contingent Consideration Regulatory Milestones; Counterparty Name= Ladrx; Type Of Arrangement= Assignment And Assumption Agreement And Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20241231 | Contingent Consideration Under Purchase Agreements | 3000000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Deferred Income Current | 1400000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Health Care Royalty Partners Two Limited Partners; Type Of Arrangement= Royalty Interest Acquisition Agreements; | ||
| 0001558370-25-007494 | 20250331 | Deferred Income Noncurrent | 4084000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Depreciation Nonproduction | 2000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Depreciation Nonproduction | 3000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Dividends Payable Current And Noncurrent | 1368000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Earnings Per Share Diluted | -0.8600 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Earnings Per Share Diluted | 0.0600 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Equity Securities Fv Ni Realized Gain Loss | -1147000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Income Not From Contract With Customer Effective Interest Rate Method | 0.0000 | USD | 1 | 0001558370-25-007494 | Counterparty Name= Affitech Research As; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20240331 | Increase Decrease In Accounts And Other Receivables | -1001000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Interest Expense Debt | 3551000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Interest Paid Net | 6078000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Investment Warrants Noncurrent | 605000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20241231 | Milestone Assets Noncurrent | 3214000.0000 | USD | 0 | 0001558370-25-007494 | Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001558370-25-007494 | 20250331 | Net Cash Provided By Used In Operating Activities | 2198000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Net Income Loss | -8595000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Single Reportable Segment; | ||
| 0001558370-25-007494 | 20240331 | Net Income Loss Available To Common Stockholders Basic | -9963000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Net Income Loss Available To Common Stockholders Diluted | -9963000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Operating Lease Payments Non Cash | -14000.0000 | USD | 1 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20241231 | Operating Lease Right Of Use Asset | 319000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Other Assets Noncurrent | 1790000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent | 45000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-007494 | 20240331 | Other Nonoperating Income Expense | 1960000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Single Reportable Segment; | ||
| 0001558370-25-007494 | 20250331 | Payment Of Consideration Under Agreements Investing Activities | 3000000.0000 | USD | 1 | 0001558370-25-007494 | Contingent Consideration By Type= Contingent Consideration Sales Milestones Four; Counterparty Name= Affitech Research As; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20250331 | Payment Of Consideration Under Agreements Investing Activities | 3000000.0000 | USD | 1 | 0001558370-25-007494 | Contingent Consideration By Type= Contingent Consideration Sales Milestones Three; Counterparty Name= Affitech Research As; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20240331 | Payments Of Financing Costs | 581000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Preferred Stock Dividend Rate Percentage | 0.0862 | pure | 4 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; | ||
| 0001558370-25-007494 | 20241231 | Preferred Stock Shares Authorized | 1000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Preferred Stock Shares Issued | 984000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; | ||
| 0001558370-25-007494 | 20250331 | Preferred Stock Shares Outstanding | 5003.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Convertible Preferred Stock; | ||
| 0001558370-25-007494 | 20250331 | Property Plant And Equipment Net | 29000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Receipts Under Agreements Investing Activities | 7771000.0000 | USD | 1 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Repayments Of Long Term Debt | 5100000.0000 | USD | 1 | us-gaap/2024 | Debt Instrument= Blue Owl Commercial Payment Backed Loan Agreement Initial Term Loan; | ||
| 0001558370-25-007494 | 20240331 | Research And Development Expense | 33000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Single Reportable Segment; | ||
| 0001558370-25-007494 | 20250331 | Research And Development Expense | 1293000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Restricted Cash Current | 1410000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20220131 | Revenue From Contract With Customer Excluding Assessed Tax | 2000000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Rezolute Inc; Type Of Arrangement= License Agreement; | ||
| 0001558370-25-007494 | 20250331 | Royalty And Commercial Payment Receivables Cost Recovery Method Long Term | 59916000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20241231 | Royalty And Commercial Payment Receivables Cost Recovery Method Short Term | 413000.0000 | USD | 0 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20240331 | Share Based Compensation | 2856000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Shares Outstanding | 11952000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-007494 | 20231231 | Stockholders Equity | 88721000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20231231 | Stockholders Equity | -1223223000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001558370-25-007494 | 20240331 | Stockholders Equity | 1314036000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007494 | 20241231 | Stockholders Equity | 1318766000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007494 | 20241231 | Stockholders Equity | 90000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-007494 | 20250331 | Stockholders Equity | 84629000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Stock Issued During Period Shares Employee Benefit Plan | 7000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-007494 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 85000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007494 | 20250331 | Stock Repurchased And Retired During Period Value | 545000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 11580000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240430 | Asset Acquisition Contingent Consideration Liability Noncurrent | 2900000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Kinnate Cvr Holders; Type Of Arrangement= Contingent Value Rights Agreement; | ||
| 0001558370-25-007494 | 20241231 | Asset Acquisition Contingent Consideration Liability Noncurrent | 3214000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001558370-25-007494 | 20241231 | Assets | 221277000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 95027000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -11389000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001558370-25-007494 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0075 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Deferred Income Current | 1370000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Income Not From Contract With Customer Effective Interest Rate Method | 253000.0000 | USD | 1 | 0001558370-25-007494 | Counterparty Name= Aptevo; Product Or Service= Ixinity; | ||
| 0001558370-25-007494 | 20250331 | Increase Decrease In Accounts Payable And Accrued Liabilities | -3265000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Increase Decrease In Deferred Revenue | -317000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -1176000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Interest Paid Net | 6100000.0000 | USD | 1 | us-gaap/2024 | Debt Instrument= Blue Owl Commercial Payment Backed Loan Agreement Initial Term Loan; | ||
| 0001558370-25-007494 | 20250228 | Investment Warrants Noncurrent | 600000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Castle Creek Biosciences Inc; Type Of Arrangement= Royalty Financing Agreement; | ||
| 0001558370-25-007494 | 20250331 | Investment Warrants Noncurrent | 605000.0000 | USD | 0 | 0001558370-25-007494 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001558370-25-007494 | 20241231 | Long Term Debt Current | 11400000.0000 | USD | 0 | us-gaap/2024 | Debt Instrument= Blue Owl Commercial Payment Backed Loan Agreement Initial Term Loan; | ||
| 0001558370-25-007494 | 20241231 | Long Term Debt Noncurrent | 106900000.0000 | USD | 0 | us-gaap/2024 | Debt Instrument= Blue Owl Commercial Payment Backed Loan Agreement Initial Term Loan; | ||
| 0001558370-25-007494 | 20240331 | Net Cash Provided By Used In Investing Activities | -7246000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Net Income Loss | -8595000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Net Income Loss | 2367000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001558370-25-007494 | 20240331 | Operating Expenses | 8494000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20240331 | Operating Income Loss | -7004000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Operating Lease Liability Current | 459000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20190930 | Payment Of Consideration Under Agreements Investing Activities | 10000000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Palobiofarma S L; Type Of Arrangement= Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20210331 | Payment Of Consideration Under Agreements Investing Activities | 13500000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Viracta Therapeutics Inc.; Type Of Arrangement= Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20230331 | Payment Of Consideration Under Agreements Investing Activities | 9600000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Aptevo; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20240331 | Payments Related To Tax Withholding For Share Based Compensation | 1334000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20241231 | Preferred Stock Shares Issued | 1600.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series B Preferred Stock; | ||
| 0001558370-25-007494 | 20241231 | Preferred Stock Shares Outstanding | 984000.0000 | shares | 0 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; | ||
| 0001558370-25-007494 | 20241231 | Preferred Stock Value | USD | 0 | us-gaap/2024 | Class Of Stock= Convertible Preferred Stock; | |||
| 0001558370-25-007494 | 20250331 | Preferred Stock Value | 49000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; | ||
| 0001558370-25-007494 | 20250331 | Prepaid Expense And Other Assets Current | 971000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Receipts Under Agreements Investing Activities | 1307000.0000 | USD | 1 | 0001558370-25-007494 | |||
| 0001558370-25-007494 | 20250331 | Restricted Cash Noncurrent | 3352000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-007494 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Alexion; Type Of Arrangement= License Agreement; | ||
| 0001558370-25-007494 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Rezolute Inc; Type Of Arrangement= License Agreement; | ||
| 0001558370-25-007494 | 20250331 | Revenue Not From Contract With Customer Units Of Revenue Method | 300000.0000 | USD | 1 | 0001558370-25-007494 | Counterparty Name= Health Care Royalty Partners Two Limited Partners; Type Of Arrangement= Royalty Interest Acquisition Agreements; | ||
| 0001558370-25-007494 | 20250331 | Royalty And Commercial Payment Receivables Cost Recovery Method Short Term | 400000.0000 | USD | 0 | 0001558370-25-007494 | Counterparty Name= Ladrx; Type Of Arrangement= Assignment And Assumption Agreement And Royalty Purchase Agreement; | ||
| 0001558370-25-007494 | 20240331 | Royalty And Commercial Payment Receivables Effective Interest Rate Method Short Term | 3000000.0000 | USD | 0 | 0001558370-25-007494 | Contingent Consideration By Type= Contingent Consideration Sales Milestones Three; Counterparty Name= Affitech Research As; Type Of Arrangement= Commercial Payment Purchase Agreement; | ||
| 0001558370-25-007494 | 20241231 | Stockholders Equity | -1237057000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001558370-25-007494 | 20250331 | Stockholders Equity | 49000.0000 | USD | 0 | us-gaap/2024 | Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; | ||
| 0001558370-25-007494 | 20250331 | Stockholders Equity | 1319607000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-007494 | 20250331 | Stockholders Equity | -1235235000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001558370-25-007494 | 20240331 | Stock Repurchased And Retired During Period Value | 13000.0000 | USD | 1 | us-gaap/2024 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Stock Options Exercised | Value of stock issued as a result of the exercise of stock options. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Operating Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Milestone Assets Noncurrent | 0001558370-25-007494 | 1 | 0 | monetary | I | D | Milestone Assets, Noncurrent | Carrying amount as of the balance sheet date of milestone assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Amount represents initial fair value in accordance with ASC 825. |
| Deferred Income Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Deferred Income, Current | Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. |
| Contingent Consideration Under Purchase Agreements | 0001558370-25-007494 | 1 | 0 | monetary | I | C | Contingent Consideration Under Purchase Agreements | Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Classified as current. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Accrual Of Contingent Consideration Under Purchase Agreements | 0001558370-25-007494 | 1 | 0 | monetary | D | C | Accrual Of Contingent Consideration Under Purchase Agreements | Accrual of contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements. |
| Royalty And Commercial Payment Receivables Cost Recovery Method Short Term | 0001558370-25-007494 | 1 | 0 | monetary | I | D | Royalty and Commercial Payment Receivables, Cost Recovery Method, Short-Term | Royalty and commercial payment receivables under cost recovery method probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Equity Securities Fv Ni | us-gaap/2024 | 0 | 0 | monetary | I | D | Equity Securities, FV-NI, Current | Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Payments Of Dividends | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments of Dividends | Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Investment Warrants Noncurrent | 0001558370-25-007494 | 1 | 0 | monetary | I | D | Investment, Warrants, Noncurrent | Fair value of investment in warrants, classified as noncurrent. |
| Additional Paid In Capital | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent | Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent. |
| Restricted Cash Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Restricted Cash, Current | Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Change In Fair Value Of Available For Sale Debt Securities Cash Equivalents | 0001558370-25-007494 | 1 | 0 | monetary | D | D | Change in Fair Value of Available-For-Sale Debt Securities, Cash Equivalents | Change in fair value of available-for-sale debt securities classified as cash equivalents. |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Net Income Loss Available To Common Stockholders Diluted | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Available to Common Stockholders, Diluted | Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Dividends Payable Current And Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Dividends Payable | Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Increase Decrease In Accounts And Other Receivables | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts and Other Receivables | The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables. |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised | Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Accrued And Other Liabilities Current | 0001558370-25-007494 | 1 | 0 | monetary | I | C | Accrued And Other Liabilities Current | Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer. |
| Stock Repurchased And Retired During Period Shares | us-gaap/2024 | 0 | 0 | shares | D | Stock Repurchased and Retired During Period, Shares | Number of shares that have been repurchased and retired during the period. | |
| Income Not From Contract With Customer Effective Interest Rate Method Cash Flow Impact | 0001558370-25-007494 | 1 | 0 | monetary | D | D | Income Not from Contract with Customer, Effective Interest Rate Method, Cash Flow Impact | Cash flow impact amount of income, not accounted for under Topic 606, in accordance with the effective interest rate method. Includes income from purchased receivables. |
| Royalty And Commercial Payment Receivables Effective Interest Rate Method Long Term | 0001558370-25-007494 | 1 | 0 | monetary | I | D | Royalty and Commercial Payment Receivables, Effective Interest Rate Method, Long-Term | Royalty and commercial payment receivables under effective interest rate method probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer. |
| Equity Securities Fv Ni Realized Gain Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Equity Securities, FV-NI, Realized Gain (Loss) | Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Preferred Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Repayments Of Long Term Debt | us-gaap/2024 | 0 | 0 | monetary | D | C | Repayments of Long-Term Debt | The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. |
| Stock Issued During Period Shares Employee Benefit Plan | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, Employee Benefit Plan | Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan. | |
| Amortization Of Financing Costs And Discounts | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Debt Issuance Costs and Discounts | Amount of amortization expense attributable to debt discount (premium) and debt issuance costs. |
| Accounts And Other Receivables Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts and Other Receivables, Net, Current | Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer. |
| Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings | us-gaap/2024 | 0 | 0 | monetary | D | D | Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings | Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Interest Expense Debt | us-gaap/2024 | 0 | 0 | monetary | D | D | Interest Expense, Debt | Amount of the cost of borrowed funds accounted for as interest expense for debt. |
| Income Taxes Paid Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Income Taxes Paid, Net | Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. |
| Preferred Stock Dividend Rate Percentage | us-gaap/2024 | 0 | 0 | percent | D | Preferred Stock, Dividend Rate, Percentage | The percentage rate used to calculate dividend payments on preferred stock. | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Preferred Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Operating Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
| Profit Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Stock Repurchased And Retired During Period Value | us-gaap/2024 | 0 | 0 | monetary | D | D | Stock Repurchased and Retired During Period, Value | Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital). |
| Accrued Preferred Stock Dividend Current | 0001558370-25-007494 | 1 | 0 | monetary | I | C | Accrued Preferred Stock Dividend, Current | Carrying value as of the balance sheet date of obligations incurred through that date and payable for preferred stock dividend. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Depreciation Nonproduction | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation, Nonproduction | The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives. |
| Intangible Assets Net Excluding Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Intangible Assets, Net (Excluding Goodwill) | Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Operating Lease Payments Non Cash | 0001558370-25-007494 | 1 | 0 | monetary | D | C | Operating Lease Payments Non Cash | Operating lease payments, non cash. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Restricted Cash Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Restricted Cash, Noncurrent | Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. |
| Payment Of Consideration Under Agreements Investing Activities | 0001558370-25-007494 | 1 | 0 | monetary | D | C | Payment of Consideration Under Agreements, Investing Activities | Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Revenues | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenues | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). |
| General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. |
| Amortization Of Intangible Assets | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Intangible Assets | The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Defined Contribution Plan Issuance Of Common Stock For Services Or Claims | 0001558370-25-007494 | 1 | 0 | monetary | D | D | Defined Contribution Plan Issuance Of Common Stock For Services Or Claims | Defined contribution plan issuance of Common stock for services or claims. |
| Royalty And Commercial Payment Receivables Cost Recovery Method Long Term | 0001558370-25-007494 | 1 | 0 | monetary | I | D | Royalty and Commercial Payment Receivables, Cost Recovery Method, Long-Term | Royalty and commercial payment receivables under cost recovery method probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer. |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Increase Decrease In Operating Lease Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Operating Lease Liability | Amount of increase (decrease) in obligation for operating lease. |
| Payments For Repurchase Of Common Stock | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments for Repurchase of Common Stock | The cash outflow to reacquire common stock during the period. |
| Interest Paid Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Interest Paid, Excluding Capitalized Interest, Operating Activities | Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Net Income Loss Available To Common Stockholders Basic | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Available to Common Stockholders, Basic | Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. |
| Payments Related To Tax Withholding For Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | C | Payment, Tax Withholding, Share-Based Payment Arrangement | Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Shares, Outstanding | Number of shares issued which are neither cancelled nor held in the treasury. | |
| Deferred Income Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Deferred Income, Noncurrent | Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. |
| Income Not From Contract With Customer Cost Recovery Method | 0001558370-25-007494 | 1 | 0 | monetary | D | C | Income Not from Contract with Customer, Cost Recovery Method | Amount of income that is not accounted for under Topic 606, in accordance with the cost recovery method. |
| Income Not From Contract With Customer Effective Interest Rate Method | 0001558370-25-007494 | 1 | 0 | monetary | D | C | Income Not from Contract with Customer, Effective Interest Rate Method | Amount of income, not accounted for under Topic 606, in accordance with the effective interest rate method. Includes income from purchased receivables. |
| Royalty And Commercial Payment Receivables Effective Interest Rate Method Short Term | 0001558370-25-007494 | 1 | 0 | monetary | I | D | Royalty and Commercial Payment Receivables, Effective Interest Rate Method, Short-Term | Royalty and commercial payment receivables under effective interest rate (EIR) method to be received within one year or the normal operating cycle, if longer. |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Asset Acquisition Contingent Consideration Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Asset Acquisition, Contingent Consideration, Liability, Noncurrent | Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent. |
| Increase Decrease In Accounts Payable And Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable and Accrued Liabilities | The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Other Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Preferred Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Payments Of Financing Costs | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments of Financing Costs | The cash outflow for loan and debt issuance costs. |
| Preferred Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Outstanding | Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. | |
| Increase Decrease In Deferred Revenue | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Deferred Revenue | Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. |
| Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | 0 | 0 | shares | D | Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period | Number of share options (or share units) exercised during the current period. | |
| Revenue Not From Contract With Customer Units Of Revenue Method | 0001558370-25-007494 | 1 | 0 | monetary | D | C | Revenue Not from Contract with Customer, Units of Revenue Method | Amount of revenue that is not accounted for under Topic 606, in accordance with the units-of-revenue method. |
| Operating Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Long Term Debt Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Long-Term Debt, Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. |
| Long Term Debt Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Long-Term Debt, Excluding Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. |
| Stock Issued During Period Value Employee Benefit Plan | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Employee Benefit Plan | Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan. |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | |
| Receipts Under Agreements Investing Activities | 0001558370-25-007494 | 1 | 0 | monetary | D | D | Receipts Under Agreements, Investing Activities | Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001558370-25-007494 | 2 | 10 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0001558370-25-007494 | 2 | 11 | BS | 0 | H | Restricted Cash Current | us-gaap/2024 | Short-term restricted cash | 0 |
| 0001558370-25-007494 | 2 | 12 | BS | 0 | H | Equity Securities Fv Ni | us-gaap/2024 | Investment in equity securities | 0 |
| 0001558370-25-007494 | 2 | 13 | BS | 0 | H | Accounts And Other Receivables Net Current | us-gaap/2024 | Trade and other receivables, net | 0 |
| 0001558370-25-007494 | 2 | 14 | BS | 0 | H | Royalty And Commercial Payment Receivables Effective Interest Rate Method Short Term | 0001558370-25-007494 | Short-term royalty and commercial payment receivables under the EIR method | 0 |
| 0001558370-25-007494 | 2 | 15 | BS | 0 | H | Royalty And Commercial Payment Receivables Cost Recovery Method Short Term | 0001558370-25-007494 | Short-term royalty and commercial payment receivables under the cost recovery method | 0 |
| 0001558370-25-007494 | 2 | 16 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses and other current assets | 0 |
| 0001558370-25-007494 | 2 | 17 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0001558370-25-007494 | 2 | 18 | BS | 0 | H | Restricted Cash Noncurrent | us-gaap/2024 | Long-term restricted cash | 0 |
| 0001558370-25-007494 | 2 | 19 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Property and equipment, net | 0 |
| 0001558370-25-007494 | 2 | 20 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | Operating lease right-of-use assets | 0 |
| 0001558370-25-007494 | 2 | 21 | BS | 0 | H | Royalty And Commercial Payment Receivables Effective Interest Rate Method Long Term | 0001558370-25-007494 | Long-term royalty and commercial payment receivables under EIR method | 0 |
| 0001558370-25-007494 | 2 | 22 | BS | 0 | H | Royalty And Commercial Payment Receivables Cost Recovery Method Long Term | 0001558370-25-007494 | Long-term royalty and commercial payment receivables under the cost recovery method | 0 |
| 0001558370-25-007494 | 2 | 23 | BS | 0 | H | Milestone Assets Noncurrent | 0001558370-25-007494 | Exarafenib milestone asset (Note 4) | 0 |
| 0001558370-25-007494 | 2 | 24 | BS | 0 | H | Investment Warrants Noncurrent | 0001558370-25-007494 | Investment in warrants | 0 |
| 0001558370-25-007494 | 2 | 25 | BS | 0 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2024 | Intangible assets, net | 0 |
| 0001558370-25-007494 | 2 | 26 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | Other assets - long term | 0 |
| 0001558370-25-007494 | 2 | 27 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0001558370-25-007494 | 2 | 30 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0001558370-25-007494 | 2 | 31 | BS | 0 | H | Accrued And Other Liabilities Current | 0001558370-25-007494 | Accrued and other liabilities | 0 |
| 0001558370-25-007494 | 2 | 32 | BS | 0 | H | Contingent Consideration Under Purchase Agreements | 0001558370-25-007494 | Contingent consideration under RPAs, AAAs, and CPPAs | 0 |
| 0001558370-25-007494 | 2 | 33 | BS | 0 | H | Operating Lease Liability Current | us-gaap/2024 | Operating lease liabilities | 0 |
| 0001558370-25-007494 | 2 | 34 | BS | 0 | H | Deferred Income Current | us-gaap/2024 | Unearned revenue recognized under units-of-revenue method | 0 |
| 0001558370-25-007494 | 2 | 35 | BS | 0 | H | Accrued Preferred Stock Dividend Current | 0001558370-25-007494 | Preferred stock dividend accrual | 0 |
| 0001558370-25-007494 | 2 | 36 | BS | 0 | H | Long Term Debt Current | us-gaap/2024 | Current portion of long-term debt | 0 |
| 0001558370-25-007494 | 2 | 37 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0001558370-25-007494 | 2 | 38 | BS | 0 | H | Deferred Income Noncurrent | us-gaap/2024 | Unearned revenue recognized under units-of-revenue method - long-term | 0 |
| 0001558370-25-007494 | 2 | 39 | BS | 0 | H | Asset Acquisition Contingent Consideration Liability Noncurrent | us-gaap/2024 | Exarafenib milestone contingent consideration (Note 4) | 0 |
| 0001558370-25-007494 | 2 | 40 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2024 | Long-term operating lease liabilities | 0 |
| 0001558370-25-007494 | 2 | 41 | BS | 0 | H | Long Term Debt Noncurrent | us-gaap/2024 | Long-term debt | 0 |
| 0001558370-25-007494 | 2 | 42 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0001558370-25-007494 | 2 | 43 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and Contingencies (Note 10) | 0 |
| 0001558370-25-007494 | 2 | 45 | BS | 0 | H | Preferred Stock Value | us-gaap/2024 | Preferred Stock | 0 |
| 0001558370-25-007494 | 2 | 46 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,952,889 and 11,952,377 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 0 |
| 0001558370-25-007494 | 2 | 47 | BS | 0 | H | Additional Paid In Capital | us-gaap/2024 | Additional paid-in capital | 0 |
| 0001558370-25-007494 | 2 | 48 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Accumulated other comprehensive income | 0 |
| 0001558370-25-007494 | 2 | 49 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0001558370-25-007494 | 2 | 50 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total stockholders' equity | 0 |
| 0001558370-25-007494 | 2 | 51 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders' equity | 0 |
| 0001558370-25-007494 | 3 | 8 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | Preferred stock, par value (in dollars per share) | 0 |
| 0001558370-25-007494 | 3 | 9 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2024 | Preferred stock, shares authorized (in shares) | 0 |
| 0001558370-25-007494 | 7 | 9 | CF | 0 | H | Amortization Of Financing Costs And Discounts | us-gaap/2024 | Accretion of long-term debt discount and debt issuance costs | 0 |
| 0001558370-25-007494 | 7 | 10 | CF | 0 | H | Operating Lease Payments Non Cash | 0001558370-25-007494 | Non-cash lease expense | 1 |
| 0001558370-25-007494 | 7 | 11 | CF | 0 | H | Equity Securities Fv Ni Realized Gain Loss | us-gaap/2024 | Change in fair value of equity securities | 1 |
| 0001558370-25-007494 | 7 | 12 | CF | 0 | H | Change In Fair Value Of Available For Sale Debt Securities Cash Equivalents | 0001558370-25-007494 | Change in fair value of available-for-sale debt securities classified as cash equivalents | 0 |
| 0001558370-25-007494 | 7 | 14 | CF | 0 | H | Increase Decrease In Accounts And Other Receivables | us-gaap/2024 | Trade and other receivables, net | 1 |
| 0001558370-25-007494 | 7 | 15 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid expenses and other assets | 1 |
| 0001558370-25-007494 | 7 | 16 | CF | 0 | H | Increase Decrease In Accounts Payable And Accrued Liabilities | us-gaap/2024 | Accounts payable and accrued liabilities | 0 |
| 0001558370-25-007494 | 7 | 17 | CF | 0 | H | Increase Decrease In Operating Lease Liability | us-gaap/2024 | Operating lease liabilities | 0 |
| 0001558370-25-007494 | 7 | 18 | CF | 0 | H | Increase Decrease In Deferred Revenue | us-gaap/2024 | Unearned revenue recognized under units-of-revenue method | 0 |
| 0001558370-25-007494 | 7 | 19 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash provided by (used in) operating activities | 0 |
| 0001558370-25-007494 | 7 | 21 | CF | 0 | H | Payment Of Consideration Under Agreements Investing Activities | 0001558370-25-007494 | Payments of consideration under RPAs, AAAs, and CPPAs | 1 |
| 0001558370-25-007494 | 7 | 22 | CF | 0 | H | Receipts Under Agreements Investing Activities | 0001558370-25-007494 | Receipts under RPAs, AAAs, and CPPAs | 0 |
| 0001558370-25-007494 | 7 | 23 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Purchase of property and equipment | 1 |
| 0001558370-25-007494 | 7 | 24 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash used in investing activities | 0 |
| 0001558370-25-007494 | 7 | 27 | CF | 0 | H | Repayments Of Long Term Debt | us-gaap/2024 | Principal payments - debt | 1 |
| 0001558370-25-007494 | 7 | 28 | CF | 0 | H | Payments Of Financing Costs | us-gaap/2024 | Debt issuance costs and loan fees paid in connection with long-term debt | 1 |
| 0001558370-25-007494 | 7 | 29 | CF | 0 | H | Payments Of Dividends | us-gaap/2024 | Payment of preferred stock dividends | 1 |
| 0001558370-25-007494 | 7 | 30 | CF | 0 | H | Payments For Repurchase Of Common Stock | us-gaap/2024 | Repurchases of common stock | 1 |
| 0001558370-25-007494 | 7 | 31 | CF | 0 | H | Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | us-gaap/2024 | Proceeds from exercise of options and other share-based compensation | 0 |
| 0001558370-25-007494 | 7 | 32 | CF | 0 | H | Payments Related To Tax Withholding For Share Based Compensation | us-gaap/2024 | Taxes paid related to net share settlement of equity awards | 1 |
| 0001558370-25-007494 | 7 | 33 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash used in financing activities | 0 |
| 0001558370-25-007494 | 7 | 34 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Net decrease in cash, cash equivalents, and restricted cash | 0 |
| 0001558370-25-007494 | 7 | 35 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash, cash equivalents, and restricted cash as of the beginning of the period | 0 |
| 0001558370-25-007494 | 7 | 36 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash, cash equivalents, and restricted cash as of the end of the period | 0 |
| 0001558370-25-007494 | 7 | 38 | CF | 0 | H | Interest Paid Net | us-gaap/2024 | Cash paid for interest | 0 |
| 0001558370-25-007494 | 7 | 39 | CF | 0 | H | Income Taxes Paid Net | us-gaap/2024 | Cash paid for taxes | 0 |
| 0001558370-25-007494 | 7 | 41 | CF | 0 | H | Accrual Of Contingent Consideration Under Purchase Agreements | 0001558370-25-007494 | Accrual of contingent consideration under the Affitech CPPA | 0 |
| 0001558370-25-007494 | 7 | 42 | CF | 0 | H | Dividends Payable Current And Noncurrent | us-gaap/2024 | Preferred stock dividend accrual | 0 |
| 0001558370-25-007494 | 3 | 10 | BS | 1 | H | Preferred Stock Dividend Rate Percentage | us-gaap/2024 | Preferred stock, dividend rate (as a percent) | 0 |
| 0001558370-25-007494 | 3 | 11 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2024 | Preferred stock, shares issued (in shares) | 0 |
| 0001558370-25-007494 | 3 | 12 | BS | 1 | H | Preferred Stock Shares Outstanding | us-gaap/2024 | Preferred stock, shares outstanding (in shares) | 0 |
| 0001558370-25-007494 | 3 | 13 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value (in dollars per share) | 0 |
| 0001558370-25-007494 | 3 | 14 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized (in shares) | 0 |
| 0001558370-25-007494 | 3 | 15 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued (in shares) | 0 |
| 0001558370-25-007494 | 3 | 16 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding (in shares) | 0 |
| 0001558370-25-007494 | 4 | 2 | IS | 0 | H | Income Not From Contract With Customer Effective Interest Rate Method | 0001558370-25-007494 | Income from purchased receivables under the EIR method | 0 |
| 0001558370-25-007494 | 4 | 3 | IS | 0 | H | Income Not From Contract With Customer Cost Recovery Method | 0001558370-25-007494 | Income from purchased receivables under the cost recovery method | 0 |
| 0001558370-25-007494 | 4 | 4 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Revenue from contracts with customers | 0 |
| 0001558370-25-007494 | 4 | 5 | IS | 0 | H | Revenue Not From Contract With Customer Units Of Revenue Method | 0001558370-25-007494 | Revenue recognized under units-of-revenue method | 0 |
| 0001558370-25-007494 | 4 | 6 | IS | 0 | H | Revenues | us-gaap/2024 | Total income and revenues | 0 |
| 0001558370-25-007494 | 4 | 8 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0001558370-25-007494 | 4 | 9 | IS | 0 | H | General And Administrative Expense | us-gaap/2024 | General and administrative | 0 |
| 0001558370-25-007494 | 4 | 10 | IS | 0 | H | Amortization Of Intangible Assets | us-gaap/2024 | Amortization of intangible assets | 0 |
| 0001558370-25-007494 | 4 | 11 | IS | 0 | H | Operating Expenses | us-gaap/2024 | Total operating expenses | 0 |
| 0001558370-25-007494 | 4 | 12 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Income (loss) from operations | 0 |
| 0001558370-25-007494 | 4 | 14 | IS | 0 | H | Interest Expense Debt | us-gaap/2024 | Interest expense | 1 |
| 0001558370-25-007494 | 4 | 15 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2024 | Other (expense) income, net | 0 |
| 0001558370-25-007494 | 4 | 16 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net income (loss) | 0 |
| 0001558370-25-007494 | 4 | 17 | IS | 0 | H | Net Income Loss Available To Common Stockholders Basic | us-gaap/2024 | Net income (loss) available to (attributable to) common stockholders, Basic | 0 |
| 0001558370-25-007494 | 4 | 18 | IS | 0 | H | Net Income Loss Available To Common Stockholders Diluted | us-gaap/2024 | Net income (loss) available to (attributable to) common stockholders, Diluted | 0 |
| 0001558370-25-007494 | 4 | 19 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Net income (loss) per share available to (attributable to) common stockholders, Basic (in dollars per share) | 0 |
| 0001558370-25-007494 | 4 | 20 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Net income (loss) per share available to (attributable to) common stockholders, Diluted (in dollars per share) | 0 |
| 0001558370-25-007494 | 4 | 21 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Weighted average shares used in computing net income (loss) per share available to (attributable to) common stockholders, Basic (in shares) | 0 |
| 0001558370-25-007494 | 4 | 22 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Weighted average shares used in computing net income (loss) per share available to (attributable to) common stockholders, Diluted (in shares) | 0 |
| 0001558370-25-007494 | 5 | 1 | CI | 0 | H | Net Income Loss | us-gaap/2024 | Net Income (Loss) | 0 |
| 0001558370-25-007494 | 5 | 2 | CI | 0 | H | Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent | us-gaap/2024 | Net unrealized gain on available-for-sale debt securities | 0 |
| 0001558370-25-007494 | 5 | 3 | CI | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Comprehensive income (loss) | 0 |
| 0001558370-25-007494 | 6 | 16 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance at beginning of period | 0 |
| 0001558370-25-007494 | 6 | 17 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Balance at beginning of period (in shares) | 0 |
| 0001558370-25-007494 | 6 | 18 | EQ | 0 | H | Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | Exercise of stock options | 0 |
| 0001558370-25-007494 | 6 | 19 | EQ | 0 | H | Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | Exercise of stock options (in shares) | 0 |
| 0001558370-25-007494 | 6 | 20 | EQ | 0 | H | Stock Issued During Period Value Employee Benefit Plan | us-gaap/2024 | Issuance of common stock related to 401(k) contribution | 0 |
| 0001558370-25-007494 | 6 | 21 | EQ | 0 | H | Stock Issued During Period Shares Employee Benefit Plan | us-gaap/2024 | Issuance of common stock related to 401(k) contribution (in shares) | 0 |
| 0001558370-25-007494 | 6 | 22 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Stock-based compensation expense | 0 |
| 0001558370-25-007494 | 6 | 23 | EQ | 0 | H | Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings | us-gaap/2024 | Preferred stock dividends | 1 |
| 0001558370-25-007494 | 6 | 24 | EQ | 0 | H | Stock Repurchased And Retired During Period Value | us-gaap/2024 | Repurchase of common stock | 1 |
| 0001558370-25-007494 | 6 | 25 | EQ | 0 | H | Stock Repurchased And Retired During Period Shares | us-gaap/2024 | Repurchase of common stock (in shares) | 1 |
| 0001558370-25-007494 | 6 | 26 | EQ | 0 | H | Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent | us-gaap/2024 | Net unrealized gain on available-for-sale debt securities | 0 |
| 0001558370-25-007494 | 6 | 29 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net Income (Loss) | 0 |
| 0001558370-25-007494 | 6 | 30 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance at end of period | 0 |
| 0001558370-25-007494 | 6 | 31 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Balance at end of period (in shares) | 0 |
| 0001558370-25-007494 | 7 | 2 | CF | 0 | H | Profit Loss | us-gaap/2024 | Net income (loss) | 0 |
| 0001558370-25-007494 | 7 | 4 | CF | 0 | H | Income Not From Contract With Customer Effective Interest Rate Method Cash Flow Impact | 0001558370-25-007494 | Adjustment for income from EIR method purchased receivables | 0 |
| 0001558370-25-007494 | 7 | 5 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation expense | 0 |
| 0001558370-25-007494 | 7 | 6 | CF | 0 | H | Defined Contribution Plan Issuance Of Common Stock For Services Or Claims | 0001558370-25-007494 | Common stock contribution to 401(k) | 0 |
| 0001558370-25-007494 | 7 | 7 | CF | 0 | H | Amortization Of Intangible Assets | us-gaap/2024 | Amortization of intangible assets | 0 |
| 0001558370-25-007494 | 7 | 8 | CF | 0 | H | Depreciation Nonproduction | us-gaap/2024 | Depreciation | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |